NCT07358520Not yet recruitingPhase 4
Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients
Prospective, Multicenter, Parallel-Controlled Clinical Study on the Use of Huaier Granules for the Treatment of Bevacizumab- and Anlotinib-Related Proteinuria in Lung Cancer Patients
Source: ClinicalTrials.gov · Last updated 22 Jan 2026
Brief summary (registry, in English)
This study is a prospective, multicenter, parallel-controlled clinical trial designed to evaluate the therapeutic efficacy of Huaier Granules for proteinuria occurring in lung cancer patients undergoing treatment with either Bevacizumab or Anlotinib.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 14 Jan 2026
- Start date
- 28 Jan 2026
- Primary completion date
- 28 Jan 2027
- Lead sponsor
- Fudan University
- Diseases
- Lung cancer
- NCT number
- NCT07358520
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 40
- From 28 Jan 2026 to the primary completion date, 28 Jan 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Inability to take oral medication;
- Required or ongoing use of drugs known to potentially affect proteinuria, including but not limited to ACE inhibitors, glucocorticoids (\>3 weeks), and Chinese patent medicines (as per respective drug prescribing information);
- Currently participating in other clinical trials investigating drugs for treating proteinuria;
Other illness
- Known allergy, contraindication, or caution to any component of Huaier Granules;
- Proteinuria caused by underlying diseases, including but not limited to nephropathy, hypertension, urinary tract infection, systemic lupus erythematosus, multiple myeloma, etc.;
Other
- Women who are pregnant, breastfeeding, or planning pregnancy;
- Refusal to cooperate with follow-up;
- Any other reasons deemed by the investigator as unsuitable for participation in this study.
Who the study is looking for
- Age ≥18 years;
- Histopathologically confirmed diagnosis of lung cancer;
- Receiving Bevacizumab or Anlotinib treatment;
- Positive urine protein detection, with 0.15g \< 24-hour urinary protein quantification \< 3.5g;
- No treatment with Huaier Granules within one month prior to enrollment;
- Expected survival time not less than 6 months;
- Voluntary participation in this study and provision of signed informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
| Xuzhou Central Hospital Coordinator of this site? Confirm its status | Xuzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.